IAXO-103 (CD14/TLR4 Antagonist) (synthetic) [1202208-36-3]

Innaxon

IAXO-103 (CD14/TLR4 Antagonist) (synthetic) [1202208-36-3]

10

1202208-36-3

Research Use Only

>98%

Non-hazardous

C42H78INO2

755.98g/mol (iodide salt)

CD14/TLR4 antagonist. Inhibitor of sterile inflammation. Synthetic TLR4/CD14 ligand with TLR4 modulating activities in vitro, and conferring protection against TLR4/CD14-mediated tissue damage and inflammation in vivo. Useful to explore CD14- dependent and TLR4-independent pathways and TLR4 activation by endogenous ligands (e.g. hyaluronic acid oligosaccharides, oxLDL, HMGB1) in sterile inflammation. Shown to inhibit neuropathic pain, secondary necrosis of acute drug-induced liver failure and vascular inflammation, and abdominal aortic aneurysm by blocking non-hematopoietic TLR4 signaling. Useful tool, where inhibition of sterile (auto-) inflammation is desired, without compromising TLR4s key role in the defense of pathogens. - Chemical. CAS: 1202208-36-3. Formula: C42H78INO2. MW: 755.98g/mol (iodide salt). Synthetic. CD14/TLR4 antagonist. Inhibitor of sterile inflammation. Synthetic TLR4/CD14 ligand with TLR4 modulating activities in vitro, and conferring protection against TLR4/CD14-mediated tissue damage and inflammation in vivo. Useful to explore CD14- dependent and TLR4-independent pathways and TLR4 activation by endogenous ligands (e.g. hyaluronic acid oligosaccharides, oxLDL, HMGB1) in sterile inflammation. Shown to inhibit neuropathic pain, secondary necrosis of acute drug-induced liver failure and vascular inflammation, and abdominal aortic aneurysm by blocking non-hematopoietic TLR4 signaling. Useful tool, where inhibition of sterile (auto-) inflammation is desired, without compromising TLR4s key role in the defense of pathogens.

C[N+](C)(C1CCCC1)CC2=CC(OCCCCCCCCCCCCCC)=C(OCCCCCCCCCCCCCC)C=C2.[I-]

2°C to 8°C

12352200